Insight Molecular Diagnostics Inc. Common Stock logo

Insight Molecular Diagnostics Inc. Common Stock (IMDX) Q3 2024 Earnings

IMDX·Reported November 12, 2024·After market close

Insight Molecular Diagnostics Inc. Common Stock reported Q3 2024 revenue of $115.0K, beat analyst consensus of $101.7K by $13.3K. Diluted EPS came in at $-0.98, missed the $-0.44 consensus by $0.54.

Revenue
$115.0Kbeat by $13.3K
Consensus: $101.7K
Diluted EPS
$-0.98missed by $0.54
Consensus: $-0.44
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-24-125365

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about Insight Molecular Diagnostics Inc. Common Stock's Q3 2024 earnings report.

Insight Molecular Diagnostics Inc. Common Stock (IMDX) reported Q3 2024 earnings on November 12, 2024 after market close.

Insight Molecular Diagnostics Inc. Common Stock reported revenue of $115.0K and diluted EPS of $-0.98 for Q3 2024.

Revenue beat the consensus estimate of $101.7K by $13.3K. EPS missed the consensus estimate of $-0.44 by $0.54.

You can read the 10-Q periodic report (0000950170-24-125365) directly on SEC EDGAR. The filing index links above go to sec.gov.